Overview of the global HPV testing market
The global human papillomavirus (HPV) testing market is anticipated to grow rapidly and will post a CAGR of more than 16% during the forecast period. The increasing trend of early detection to prevent the growing prevalence of cervical cancer will drive the growth prospects for the global HPV testing market until the end of 2020. The increasing adoption of HPV tests among women will enable the early detection of high-risk HPV genotypes such as HPV 16, 18, 31, 33, 45, and others. Also, since the government has released guidelines in various countries recommending women aged 26-65 years to undergo HPV testing for the early detection of cervical cancer, the adoption of HPV testing is increasing. Some of the countries who have benefitted from early detection due to government regulations include regions such as Americas, EMEA, and APAC. Since the Affordable Care Act in the US has increased the adoption of HPV testing, around 75% of women have undergone early diagnosis. Similarly, the government initiatives in Germany to invite women aged between 20 and 60 in 2018 will drive the adoption rate of the testing kit. Furthermore, the changes made in National Cervical Screening Program of 2016 in New Zealand, APAC, to include women aged between 20 to 25 years will boost awareness about cervical cancer among women.
In terms of geography, the Americas accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in North America is the growing number of cervical cancer patients, which accounts for more than 13,000 cases each year. Also, the government initiatives in various countries such as the US, Canada, and Brazil, the awareness and adoption of HPV testing is increasing. Furthermore, the increasing government funding will also drive the market’s growth in the region.
Competitive landscape and key vendors
The global HPV testing market is highly competitive and diversified due to the presence of Tier 1 and Tier 2 and small companies. Also, the increasing number of test kit manufacturing companies will intensify the competitive environment in the market. It has been observed that the distribution partnerships can help the Tier 1 and Tier 2 companies to grow in the market. Furthermore, these vendors compete against each other based on the factors such as competitive pricing, product differentiation, technology and imaging software update, online and on-site servicing, a partnership with training clinics and governments, and attending medical expos or trade fairs.
Key vendors in this market are -
- Abbott Laboratories
- BD
- Roche Diagnostics
- Qiagen
Other prominent vendors in the market include Arbor Vita, Breakspear Medical, Cepheid, DAAN Gene, DiaCarta, Delphi Bioscience, Fujirebio Diagnostics, Genera Biosystems, IncellDx, OralDNA Labs, Seegene, SoloPap, and Trovagene.
Segmentation by product and analysis of the HPV testing market
The HPV testing consumables accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. One of the major factors responsible for the market segment’s growth is the availability of test assays and accessories such as vials.
Segmentation by end user and analysis of the HPV testing market
- Clinical diagnostic laboratories
- Physicians' office laboratories
- Hospitals
The clinical diagnostic laboratories segment accounted for the maximum market share during 2015 and will continue to dominate the market during the forecast period. One of the major factors responsible for the market segment’s growth is the increasing number of reference laboratories that form a partnership with large hospitals and clinics.
Key questions answered in the report include
- What will the HPV testing market size and the growth rate be in 2020?
- What are the key factors driving the global HPV testing market?
- What are the key HPV testing market trends impacting the growth?
- What are the challenges to market growth?
- Who are the key vendors in the global HPV testing market?
- What are the market opportunities and threats faced by the vendors in the global HPV testing market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global HPV testing market?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Cervical cancer diagnosis by HPV testing
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Market segmentation by product
- Global HPV testing market by systems
- Global HPV testing market by consumables
PART 07: Market segmentation by end-user
- Hospitals
- Clinical diagnostic laboratories
- Physicians' office laboratories
PART 08: Geographical segmentation
- HPV testing market in Americas
- HPV testing market in EMEA
- HPV testing market in APAC
PART 09: Market drivers
- Early detection of cervical cancer to prevent the growing prevalence
- Paradigm shift toward use of HPV home-testing kits
- Reimbursements for HPV tests
PART 10: Impact of drivers
PART 11: Market challenges
- Pap test: Alternative diagnostic test for cervical cancer screening
- Limited number of health clinics and healthcare settings in developing countries
- Lack of uniformity in screening policies
PART 12: Impact of drivers and challenges
PART 13: Market trends
- Expansion of companies in key markets
- Co-testing with HPV and Pap tests
- Development of mRNA HPV test
PART 14: Vendor landscape
- Competitive landscape analysis
PART 15: Key vendor analysis
- Abbott Laboratories
- BD
- Roche Diagnostics
- Qiagen
- Hologic
- Other prominent vendors
PART 16: Appendix
PART 17: Explore Technavio